Offline
| Post a Message | Explore Forums | Browse Stock Messages | Hot Discussions | Top rated Messages | Top Boarders | |
|
|
|
Ranbaxy Laboratories
NSE Announcements on Ranbaxy Labs
Posted by :
MMB MessengerTracked by: 0 Boarder
Ranbaxy Laboratories Ltd has informed the Exchange that the auditors have conducted the limited review of the unaudited financial results for the quarter ended September 30, 2008. A copy of the Limited Review report shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). ...
FDA Sending Inspectors to Other Nations
Posted by : sambalaTracked by: 0 Boarder
Lucky promoters miss market crash, strike gold
NEW DELHI: A handful of Indian promoters have made a killing amidst the market mayhem. They were lucky enough to sell their companies at massive premiums this year, narrowly escaping the steep Sensex fall of the last two months.
The Singh brothers sold Ranbaxy in June at a 71% premium over the existing share price, Parikhs sold Zandu Pharma in October at a 54% premium to the latest price, BK Modi sold Spice Communications to Idea Cellular in June at a 52% premium, Burmans sold Dabur Pharma in April at a 56% premium, e4e sold Aztecsoft in May at a 55% premium and, in the same month, IL&FS and US-based brokerage firm E*Trade sold their stakes in IL&FS Investsmart to HSBC at a 63% premium.
These deals were sealed just before the market crashed to sub-10,000 levels. While the stock market started moving down after hitting a peak in January 2008, it had stabilised at 14,000-15,000 in August. But with large US financial services companies going belly up in September, the markets witnessed a fresh round of selling. Sensex, the bellwether stock market index, has lost 36% value since September 14.
Promoters of companies who negotiated the sales can now look back and call it “a close shave.’’ “Usually, when the market trades at a fair price, sellers look at a premium of 15-30%,’’ says advisory firm Grant Thornton’s M&A head Pankaj Karna. But, he adds, “Premiums that sellers command varies across companies. So a billion-dollar company which has a key position in its industry would get higher premium even when markets are trading at a fair price. Given today’s valuations, some promoters can even look at premiums which are in triple digits.”
Some of the deals were finalised when prices were relatively closer to the stock market prices. For instance, owners of textiles exporter Gokaldas Exports had announced they were selling stake to private equity firm Blackstone in August 2007 at Rs 275/share, a premium of 19.5%. The scrip, which rose to a high of Rs 299/share in January, closed at Rs 94.25 on the BSE on Wednesday. Ranbaxy promoters sealed the best deal, selling their company to Japanese drug maker Daichii Sankyo in June at Rs 737/share, a 31% premium to the ruling market price.
The stock price was down to Rs 213 on Wednesday. In the case of Zandu Pharma, the company saw the Vaidyas, one of its co-promoters, selling out to
Emami at an estimated Rs 8,000/share. The other owner of Zandu Pharma, the Parikhs, went to court claiming right of first refusal for Vaidyas’ share. Last month, the Parikhs finally settled their dispute with Emami and sold their entire 18.18% stake at Rs 15,000/share in addition to a non-compete fee of Rs 22 crore. The Zandu Pharma scrip is now down to Rs 6,485/share.
It is not just the promoters who struck gold. Other shareholders who sold their equity in the mandatory open offer that followed the sell-out by the promoter also benefited. But these shareholders, which includes institutional investors and retail shareholders, could sell only part of their holdings as the acquirers made an offer to buy 20% of the target company as required by the regulations. As a result other investors could tender only a part of their total holdings in the offer. There were also deals where only the minority shareholder cashed out at a premium.
In UTV Software, in which Disney acquired a majority stake, the promoters did not sell out. Instead, Disney was issued new shares at a premium and thereafter it came up with an open offer to buy more shares. The offer was made to minority shareholders at a price of Rs 860.79—more than triple of Rs 242, the last trading price of UTV Software at BSE on Wednesday.
...
In reply to:
FDA Sending Inspectors to Other Nations
Posted by : sambala
WASHINGTON – The U.S. Department of Health and Human Services will send the first U.S. Food and Drug Administration staff to China, India, Europe, and Latin America before the end of 2008.
“We’re making steady progress to better safeguard our supply of food and medicines, though much work remains,” said Health and Human Services Secretary Mike Leavitt. “In the past year, we’ve upgraded labs and equipment, hired additional staff, and begun implementing product safety agreements with key trading partners, including China.
“Increasing our presence overseas will provide greater protections to American consumers at home and benefit our host countries as well,” he added. “Opening these offices will mark a key milestone in the globalization of our efforts to enhance the safety of imported food and medical products.”
“The globalization of the food supply and medical product manufacturing has demanded that we do things differently,” said FDA Commissioner Andrew C. von Eschenbach. “Through our Beyond our Borders initiative, we won’t have to send our experts to another country to work with foreign governments and regulated industry to improve our oversight – we’ll have staff living there and working on the ground 365 days a year.”
The first overseas office will be in China. The U.S. government recently secured formal approval for the office from the People’s Republic of China. The first staff will be in place in Beijing this year, with additional staff to be posted in 2009. Staff is also scheduled to be posted in Shanghai and Guangzhou next year. The department anticipates a total of eight U.S. nationals in China. Secretary Leavitt is scheduled to travel to China in November to meet with Chinese health officials to review mutual efforts to ensure the safety of food and medical products consumed by the two nations, particularly imported goods.
The Health Department and FDA plan on establishing its second overseas office in the Republic of India, with staff first posting to New Delhi in 2008 and at least one additional office to follow in 2009. Plans at present are for 10 U.S. nationals to be posted in India. The U.S. government is in the process of pursuing India’s formal approval.
In both nations, personnel would work closely with local authorities as well as industries that ship food and medical products to the United States to improve safety efforts. Their activities will include providing technical advice, conducting additional inspections and working with government agencies and private sector entities interested in developing certification programs.
Short Term Target - 240
Posted by :
shah_chirag_bTracked by: 1 Boarder
Buy Ranbaxy At Current Levels, It Will Reach 240/- Due to Buy Back of Shares...
this
Posted by : gkmurthy1748Tracked by: 0 Boarder
this co can`t recover ============pl be away ==================...
Ranbaxy Fine likely to scrap US buyout plan
Posted by :
morningdewTracked by: 0 Boarder
MUMBAI: Ranbaxy Fine Chemical’s (RFCL) plans to acquire the US-based speciality chemicals maker Mallinckrodt Baker is facing delays because of
valuation problems. The deal, which was earlier in the region of $325-350 mn, is being revalued in the wake of the global slowdown and poor earnings of the foreign company in the year ended September 2008, sources familiar with the situation said.
In addition, I-Ventures’ plan to part-finance the acquisition by selling a stake in RFCL to private equity investors is learnt to have evoked a tepid response. By some accounts, the deal may even fall through.
A source close to the development said I-Ventures will wait till the announcement of the US company’s December quarter results before putting a fresh price tag to the deal. Another source in a big private equity fund said P-E players may not participate in funding of the acquisition. “RFCL is a good company but it may find difficult to run a US company, which is thrice its size.
Under the changed scenario, I will be surprised if I-Ventures manages to get funding from PE players,” he said. The person close to the deal said I-Ventures has been in talks to acquire Mallinckrodt Baker since August this year. “The entire global financial markets have changed since September. Hence, it’s only logical that the deal needs revaluation.”
When contacted, a senior I-Venture official chose not to comment because his firm had signed a non-disclosure agreement with Mallinckrodt Baker. RFCL MD Sushil Mehta told ET: “As a company policy, we do not comment on market speculations.”
ET had earlier reported on the possibility of the deal in early September, before the US financial slowdown resulted in a world-wide contagion. It is learnt that I-Ventures had decided two months ago that it would raise around $100 million as equity from third-party private equity investors and would mobilise the remaining funds by way of debt from ICICI Bank. If I-Venture fails to raise funds from P-E players, it will have to organise more debt, which is not an easy proposition in the tight money market.
If the deal falls through, it will be the second instance of an Indian company backing out of a foreign acquisition because of valuation. Last month, Sterlite Industries had pulled out of its proposed acquisition of the US copper mining company, Asarco, in the wake of the credit crunch and falling copper prices. However, Sterlite had backed out of the transaction after signing a formal agreement with Asarco. In this case, I-Ventures is yet to sign any definitive deal for the purchase of Mallinckrodt Baker.
The RFCL-Mallinckrodt Baker deal, if consummated, will make RFCL a critical player in the consolidating global fine chemicals industry, especially in the laboratory products space. RFCL has three divisions: animal health care, fine chemicals and the diagnostics business. Mallinckrodt Baker is part of the $10-billion healthcare giant Covidien, formerly Tyco Healthcare.
It has over 2,000 employees in four plants in the US, the Netherlands, Mexico and Malaysia. I-Ventures had bought RFCL three years ago for Rs 125 crore. UK-based GLG Partners had also invested close to $20 mn in the company last year.
[ET]...
FDA Sending Inspectors to Other Nations
Posted by : sambalaTracked by: 0 Boarder
WASHINGTON – The U.S. Department of Health and Human Services will send the first U.S. Food and Drug Administration staff to China, India, Europe, and Latin America before the end of 2008.
“We’re making steady progress to better safeguard our supply of food and medicines, though much work remains,” said Health and Human Services Secretary Mike Leavitt. “In the past year, we’ve upgraded labs and equipment, hired additional staff, and begun implementing product safety agreements with key trading partners, including China.
“Increasing our presence overseas will provide greater protections to American consumers at home and benefit our host countries as well,” he added. “Opening these offices will mark a key milestone in the globalization of our efforts to enhance the safety of imported food and medical products.”
“The globalization of the food supply and medical product manufacturing has demanded that we do things differently,” said FDA Commissioner Andrew C. von Eschenbach. “Through our Beyond our Borders initiative, we won’t have to send our experts to another country to work with foreign governments and regulated industry to improve our oversight – we’ll have staff living there and working on the ground 365 days a year.”
The first overseas office will be in China. The U.S. government recently secured formal approval for the office from the People’s Republic of China. The first staff will be in place in Beijing this year, with additional staff to be posted in 2009. Staff is also scheduled to be posted in Shanghai and Guangzhou next year. The department anticipates a total of eight U.S. nationals in China. Secretary Leavitt is scheduled to travel to China in November to meet with Chinese health officials to review mutual efforts to ensure the safety of food and medical products consumed by the two nations, particularly imported goods.
The Health Department and FDA plan on establishing its second overseas office in the Republic of India, with staff first posting to New Delhi in 2008 and at least one additional office to follow in 2009. Plans at present are for 10 U.S. nationals to be posted in India. The U.S. government is in the process of pursuing India’s formal approval.
In both nations, personnel would work closely with local authorities as well as industries that ship food and medical products to the United States to improve safety efforts. Their activities will include providing technical advice, conducting additional inspections and working with government agencies and private sector entities interested in developing certification programs.
...
Ranbaxy Open Offer Goof up : Did Small shareholders benefit?
Posted by : GuestTracked by: 0 Boarder
dont dwell on the past. All wounded bulls move ahead... lets maul the bears... 20 % open offer of Ranbaxy is old and gone...
Singh will reduce Corporate Tax to 17 % / personal IT to 10 %. So no money laundering. All cos will report historically high profits... PM Singh will be remembered as a KING....
In reply to:
Ranbaxy Open Offer Goof up : Did Small shareholders benefit?
Posted by : Guest
if anyone had seen the ratio of oversubcription of Ranbaxy open offer at 20%, there will be obvious question as to whether it was really low or intended to be kept lower. I, being a long time shareholder lost the opportunity as the registrar to the issue did not deliver the open offer letter to me. A message sent to Investor relations department has not be responded.
Tracked by: 0 Boarder
All fools who short sell ranbaxy will burn themselves. in 2001 / 2004 Ranbaxy moved from 400 to 1600. Then it was a 10 rupee share. Clinton is code for Ranbaxy... Share can move to atleast 800 if lady clinton is elected SS of USA. 2010 - awarded 80 mg, 180 excl for ATORVASTATIN. Sardar is slowly buying stock at 200 - 300 in this market turmoil. Japs are really no fools. See Suzuki Car Co. Even toyota is suffering for not entering India then. For Suzuki, they do not fear market share loss / Recession for atleat another 10 years. India is the key in this market turmoil. ...
In reply to:
Guest
yah the japs are upto something big. Slowly entering india... 26% tata teleservices, when there is so much competition. When democrat clinton was in power, ranbaxy gained, now with democrat obama in power, hmmm. maybe ranbaxy will touch 1000 soon.
Tracked by: 0 Boarder
yah the japs are upto something big. Slowly entering india... 26% tata teleservices, when there is so much competition. When democrat clinton was in power, ranbaxy gained, now with democrat obama in power, hmmm. maybe ranbaxy will touch 1000 soon. ...
In reply to:
Guest
All said and done, Japs are no fools. 700+ they brought sizeable nos of shares. now they they dont care if the share price is 230 or 100, sales to japan and usa could reach 10 billion from this plant, profit could be transferred to japan. After all japan and USA are constitute 80 % of world market. So Japan is king of singhs. Not money launders like indians, who cheat the nation, save taxes by siponing funds to switzerland and dubai and and.... and... only for the banks in these countries to go bust. Let ten industrialist build ten bridges in one year and see the development. Useless people of india know to kill poor people in the name of religion, caste, creed. Shameless Indians... dont admire the kids, their family started with money lending, so the grandsons may have done some deal with Daichi - that`s why the share of this company is low. They know the game... Now they must be accumulating the shares which are beaten down due to negative news....
Ranbaxy Open Offer Goof up : Did Small shareholders benefit?
Posted by : GuestTracked by: 0 Boarder
you can always download from the net. Singh cannot come and deliver the letter to you in this net age !...
In reply to:
Ranbaxy Open Offer Goof up : Did Small shareholders benefit?
Posted by : Guest
Hi! I also got the open offer letter after the deadline had expired. Wonder how many more such cases are out there.
Opinder
Ranbaxy Open Offer Goof up : Did Small shareholders benefit?
Posted by : GuestTracked by: 0 Boarder
Hi! I also got the open offer letter after the deadline had expired. Wonder how many more such cases are out there.
Opinder...
In reply to:
Ranbaxy Open Offer Goof up : Did Small shareholders benefit?
Posted by : Guest
What man what you are talking they were advertising every were you sleeping.
US - FDA puts Lupin plant under inspection.
Posted by :
pyaretajTracked by: 0 Boarder
Bad news came in today for Lupin. Like Ranbaxy, United States FDA has put one of Lupin`s plant under interrogation, sighting evidence that their manufacturing plant has discrepency. This is bad news for Lupin today, just like how it was for Ranbaxy. With this move, Lupin might see a drastic fall in coming days, starting tomorrow (Friday).
As I am not an investor in Lupin, I advise all investors of Lupin to be cautious and follow up news closely. Those who are in profit, its time to sell and buy on lower levels. Do not panic but make your moves sensibly.
Good luck....
...
Buy Ranbaxy Labs, target of Rs 316: Angel
Posted by : MMB MessengerTracked by: 0 Boarder
Angel Broking has maintained its buy rating on Ranbaxy Laboratories with a target of Rs 316. For the quarter, the company posted Net Sales of Rs 1,882 crore, registering a yoy growth of 14.7%....
Ranbaxy Open Offer Goof up : Did Small shareholders benefit?
Posted by : GuestTracked by: 0 Boarder
What man what you are talking they were advertising every were you sleeping.
...
In reply to:
Ranbaxy Open Offer Goof up : Did Small shareholders benefit?
Posted by : Guest
if anyone had seen the ratio of oversubcription of Ranbaxy open offer at 20%, there will be obvious question as to whether it was really low or intended to be kept lower. I, being a long time shareholder lost the opportunity as the registrar to the issue did not deliver the open offer letter to me. A message sent to Investor relations department has not be responded.
Tracked by: 0 Boarder
All said and done, Japs are no fools. 700+ they brought sizeable nos of shares. now they they dont care if the share price is 230 or 100, sales to japan and usa could reach 10 billion from this plant, profit could be transferred to japan. After all japan and USA are constitute 80 % of world market. So Japan is king of singhs. Not money launders like indians, who cheat the nation, save taxes by siponing funds to switzerland and dubai and and.... and... only for the banks in these countries to go bust. Let ten industrialist build ten bridges in one year and see the development. Useless people of india know to kill poor people in the name of religion, caste, creed. Shameless Indians... dont admire the kids, their family started with money lending, so the grandsons may have done some deal with Daichi - that`s why the share of this company is low. They know the game... Now they must be accumulating the shares which are beaten down due to negative news.......
In reply to:
Guest
thanks for you note though it was very long
but one has to admire the singh brothers for having timed their exit so well - they have got 5 times what they would have got now. makes me wonder if religare where elder brother is bringing rights issue should be seriously considered. after all if someone can sell so called family silver at 5 times its worth then those guys have financial acumen. singh is king
Boarders Outlook on Ranbaxy Labs
positive outlook4 queries on Ranbaxy Labs
see moreMore from the Pharmaceuticals Sector
Boarders tracking Ranbaxy Labs
see more News Updates on Ranbaxy Labs
